Takeda Pharmaceuticals U.S.A., Inc. Sustainability Profile
Takeda Pharmaceuticals U.S.A., Inc., a subsidiary of Takeda Pharmaceutical Company Limited, is a leading global biopharmaceutical firm headquartered in the United States. Established in 1781, Takeda has evolved into a powerhouse in the pharmaceutical industry, focusing on areas such as oncology, gastroenterology, neuroscience, and rare diseases. With a commitment to innovation, Takeda offers a diverse portfolio of core products, including advanced therapies that address unmet medical needs. The company is recognised for its patient-centric approach and dedication to research and development, which has led to significant breakthroughs in treatment options. As a prominent player in the biopharmaceutical sector, Takeda has achieved notable milestones, including strategic acquisitions and partnerships that enhance its market position. With a strong presence in North America and beyond, Takeda Pharmaceuticals continues to shape the future of healthcare through its unwavering commitment to improving patient outcomes.
DitchCarbon Score
How does Takeda Pharmaceuticals U.S.A., Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Takeda Pharmaceuticals U.S.A., Inc.'s score of 72 is higher than 83% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Takeda Pharmaceuticals U.S.A., Inc. currently does not report specific carbon emissions data, as there are no available figures for emissions in kg CO2e. However, the company is part of a broader commitment to climate action through its parent organisation, Takeda Pharmaceutical Company Limited. As a current subsidiary, Takeda Pharmaceuticals U.S.A. inherits climate initiatives and targets from Takeda Pharmaceutical Company Limited, which has set ambitious goals to reduce its carbon footprint. These initiatives include participation in the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP), both of which aim to align corporate emissions reductions with climate science. While specific reduction targets for Takeda Pharmaceuticals U.S.A. are not detailed, the overarching commitments from its parent company indicate a strong focus on sustainability and climate responsibility. The company is also involved in initiatives such as RE100 and the Climate Pledge, further demonstrating its dedication to reducing environmental impact. In summary, while specific emissions data for Takeda Pharmaceuticals U.S.A., Inc. is not available, the company is actively engaged in climate commitments through its parent organisation, Takeda Pharmaceutical Company Limited, which sets the framework for its sustainability efforts.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Scope 1 | 96,000,000 | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 161,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 |
| Scope 3 | 226,000,000 | 000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
How Carbon Intensive is Takeda Pharmaceuticals U.S.A., Inc.'s Industry?
How Carbon Intensive is Takeda Pharmaceuticals U.S.A., Inc.'s Location?
Takeda Pharmaceuticals U.S.A., Inc.'s Scope 3 Categories Breakdown
Takeda Pharmaceuticals U.S.A., Inc.'s Scope 3 emissions, which decreased by 23% last year and increased significantly since 2015, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 68% of Scope 3 emissions.
Top Scope 3 Categories
Takeda Pharmaceuticals U.S.A., Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Takeda Pharmaceuticals U.S.A., Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
